Skip to main content
TipRanks
Go Ultimate75% OFF

Haw Par (HAWPF) AI Stock Analysis

15 Followers
HAWPF

Haw Par

(Other OTC:HAWPF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Very low leverageThe exceptionally low debt burden gives Haw Par substantial financial flexibility and reduces exposure to interest costs and refinancing pressure. This conservative funding structure can help the company withstand operating volatility while preserving capacity to support healthcare growth, leisure operations, or investments.
Negative Factors
2025 revenue contractionThe reversal from several years of revenue expansion to a 2025 decline signals a meaningful slowdown in top-line momentum. Continued contraction would reduce operating leverage, constrain reinvestment in the healthcare franchise, and make it harder for the company to compound earnings over the next several quarters.

Haw Par (HAWPF) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%HAWPF-6.47%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.18B
Dividend Yield
3.08%
Average Volume (3M)
300
Price to Earnings (P/E)
12.0
Beta (1Y)
0.36
Revenue Growth
-10.44%
EPS Growth
-5.59%
Country
US
Employees
595
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Haw Par Business Overview & Revenue Model

Company Description

Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business...

Haw Par Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HAWPF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SG:BSLSG:BSL63NeutralSGD 1.58B23.096.42%3.57%-3.18%6.71%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SG:A50SG:A5046NeutralSGD 1.24B-40.27-6.42%―6.44%38.89%

* Healthcare Sector Average

Performance Comparison

-20%0%20%HAWPFSG:BSLSG:A50SG:1J5SG:40TSG:546Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HAWPF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HAWPFHaw Par Corporation 9.73-0.67-6.47%
SG:BSLRaffles Medical Group 0.84-0.11-12.04%
SG:A50Thomson Medical Group Ltd.0.05-0.01-20.34%
SG:1J5Hyphens Pharma International Ltd.0.350.025.97%
SG:40TISEC Healthcare Ltd0.31-0.00-1.27%
SG:546Medtecs International Corporation Ltd.0.10-0.02-18.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.